A Phase 3 interventional study of BMN165 20mg/day and BMN165 40mg/day in Phenylketonuria (PKU), sponsored by BioMarin Pharmaceutical. Completed at 29 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-05-21.
Sponsored by BioMarin Pharmaceutical · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing pegvaliase in Phenylketonurias — 1 open to participants now, 2 under way, 1 of them phase 3. pegvaliase · Phenylketonurias.
Among the 10 studies testing pegvaliase in Phenylketonurias, this one is the 2nd largest by enrollment, is one of 2 that started in 2013, is one of 4 in phase 3, and was the 7th registered.
191 studies on the registry are indexed under Phenylketonurias; 40 are open to participants now.
Browse Phenylketonurias studies →1 of the 10 studies testing pegvaliase in Phenylketonurias is open now, in 1 country. Recruiting first, the newest first:
BioMarin Pharmaceutical · Sites in United States
Ages 18–65
By country, each count listing its studies:
pegvaliase: first FDA approval 2018 (PALYNZIQ), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 31 Phenylketonurias studies recruiting now, 14 (45%) set no upper age limit and 17 (55%) stop at 75 or younger; 15 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2013.
This study's enrollment of 215 is above the median of 27 across 122 interventional studies indexed under Phenylketonurias.
Median enrollment 39 across the 10 interventional studies. Of the 8 that completed or were terminated, 7 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 1 most frequent:
BioMarin Pharmaceutical is the lead sponsor of 112 studies on the registry; 13 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 12 (63%) have results posted.
35 studies in Phenylketonurias by BioMarin Pharmaceutical: 3 open now, 5 under way, 1 of them phase 3. Of 29 finished, 17 (59%) have results posted.
Among the 35 studies in Phenylketonurias by BioMarin Pharmaceutical, this one is the 3rd largest by enrollment of the 26 interventional ones that give a count, is one of 3 that started in 2013, is one of 11 in phase 3, and was the 22nd registered.
BioMarin Pharmaceutical’s Phenylketonurias studies by the year they started, since 2004.
1 of the studies testing pegvaliase in Phenylketonurias that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07477691BioMarin PharmaceuticalImmune Modulation During Palynziq® Treatment in Adults (IMPALA) | 2027-09-30 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing pegvaliase in Phenylketonurias, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among BioMarin Pharmaceutical’s 35 in Phenylketonurias:
This tab as a report to print or save as PDF → With an account.
The BMN 165 clinical development program has been designed to demonstrate the safety and efficacy of BMN 165 in reducing blood Phe concentrations in adults with PKU.
165-302 is a Phase 3, 4 Part, Randomized, Double-Blind, Placebo-Controlled, Discontinuation Study to Evaluate the Efficacy and Safety of Self Administered Subcutaneous Injections of BMN 165 by Adults With PKU.
This study is open only to adults who have been exposed to BMN165 in a previous study.
Study BMN 165-302 is a four-Part, Phase 3 study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Individuals eligible to participate in this study must meet all of the following criteria:
Are at least 18 y/o and no older than 70 y/o at screening
Has identified a competent person(s) > 18 y/o who can observe the subject during study drug administration at certain points in the study
If sexually active, willing to use two acceptable methods of during and for 4 weeks after the study
Exclusion Criteria
Individuals who meet any of the following exclusion criteria will not be eligible to participate in the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMN165 20mg/day self-administered daily
Drug: BMN165 20mg/day
20 mg/day Placebo self-administered daily
Drug: Placebo
BMN165 40mg/day self-administered daily
Drug: BMN165 40mg/day
40 mg/day Placebo self-administered daily
Drug: Placebo
Drug page: Pegvaliase
BMN165 20mg/day self-administered daily
Also known as: PEG-PAL
Drug page: Pegvaliase
BMN165 40mg/day self-administered daily
Also known as: PEG-PAL
Non-drug placebo, self-administered daily
Also known as: Dextran 40
Change From Baseline in the Blood Plasma Phenylalanine (Phe) Concentration at Part 2
Blood phe concentration in subjects previously exposed to BMN165 who were administered BMN165 20 or 40 mg/day compared with those who were administered a matching placebo.
Time frame: At Part 2 baseline and change from baseline at Part 2 week 8
Change From Baseline in the Cognitive and Mood Symptoms Measured by ADHD Rating Scale (RS)-IV Inattention Subscale at Part 2
Attention deficit hyperactivity disorder rating scale IV (ADHD RS-IV) is investigator-rated, 9-item, inattention subscale score ranges from 0 to 27, with higher scores indicative of a greater degree of impairment and a baseline score \>9 indicative of a presence of symptoms.
Time frame: At Part 2 baseline and change from baseline at Part 2 week 8
Change From Baseline in the Blood Plasma Phenylalanine (Phe) Concentration at Part 4
The long term effect of multiple dose levels of BMN165 on blood phe concentration in subjects who are administered BMN165 using pre-filled syringes.
Time frame: At Part 4 week 57, 105, 161, 209 and 249
Change From Baseline in the Cognitive and Mood Symptoms Measured by PKU POMS TMD at Part 2
Phenylketonuria (PKU) Total Mood Disturbance (TMD) Profile of Mood States (POMS) PKU POMS TMD is self-rated, each item in the tool is rated using a five-point Likert scale: 0 (not at all), 1 (a little), 2 (moderately), 3 (quite a bit), and 4 (extremely).
Time frame: At Part 2 baseline and change from baseline at Part 2 week 8
Change From Baseline in the Cognitive and Mood Symptoms Measured by PKU POMS Confusion Subscale at Part 2
PKU POMS confusion mood domain (referred to as the confusion subscale) is self-rated, each item in the tool is rated using a five-point Likert scale: 0 (not at all), 1 (a little), 2 (moderately), 3 (quite a bit), and 4 (extremely).
Time frame: At Part 2 baseline and change from baseline at Part 2 week 8
Change From Baseline in the Cognitive and Mood Symptoms Measured by POMS TMD at Part 2
Full-length POMS TMD is self-rated, each item in the tool is rated using a five-point Likert scale: 0 (not at all), 1 (a little), 2 (moderately), 3 (quite a bit), and 4 (extremely).
Time frame: At Part 2 baseline and change from baseline at Part 2 week 8
This was a multicenter study, conducted in 29 study centers of United States.
| Milestone | BMN165 20mg/Day | Placebo 20mg/Day | BMN165 40mg/Day | Placebo 40mg/Day | BMN165 |
|---|---|---|---|---|---|
| Started | 86 | 0 | 78 | 0 | 0 |
| Completed | 74 | 0 | 78 | 0 | 0 |
| Not completed | 12 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 4 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 4 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 2 | 0 | 0 | 0 | 0 |
| Milestone | BMN165 20mg/Day | Placebo 20mg/Day | BMN165 40mg/Day | Placebo 40mg/Day | BMN165 |
|---|---|---|---|---|---|
| Started | 34 | 15 | 32 | 14 | 0 |
| Per amendment #2 of the protocol | 29 | 14 | 29 | 14 | 0 |
| Completed | 34 | 15 | 31 | 14 | 0 |
| Not completed | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 0 |
| Milestone | BMN165 20mg/Day | Placebo 20mg/Day | BMN165 40mg/Day | Placebo 40mg/Day | BMN165 |
|---|---|---|---|---|---|
| Started | 48 | 0 | 41 | 0 | 0 |
| Per amendment #2 of the protocol | 34 | 0 | 26 | 0 | 0 |
| Completed | 48 | 0 | 41 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
| Milestone | BMN165 20mg/Day | Placebo 20mg/Day | BMN165 40mg/Day | Placebo 40mg/Day | BMN165 |
|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 202 |
| Completed | 0 | 0 | 0 | 0 | 172 |
| Not completed | 0 | 0 | 0 | 0 | 30 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 5 |
| Withdrew: Subject withdrew consent | 0 | 0 | 0 | 0 | 14 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 4 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 5 |
| Withdrew: Protocol deviations | 0 | 0 | 0 | 0 | 2 |
Blood phe concentration in subjects previously exposed to BMN165 who were administered BMN165 20 or 40 mg/day compared with those who were administered a matching placebo.
| µmol/L | BMN165 20mg/Day | Placebo 20mg/Day | BMN165 40mg/Day | Placebo 40mg/Day |
|---|---|---|---|---|
| Part 2 Baseline | 596.8 ± 582.75 | 563.9 ± 504.62 | 410.9 ± 439.95 | 508.2 ± 363.68 |
| Change from Baseline Part 2 Week 8 | -65.9 ± 192.02 | 996.4 ± 555.00 | 114.1 ± 332.40 | 599.0 ± 507.40 |
Attention deficit hyperactivity disorder rating scale IV (ADHD RS-IV) is investigator-rated, 9-item, inattention subscale score ranges from 0 to 27, with higher scores indicative of a greater degree of impairment and a baseline score \>9 indicative of a presence of symptoms.
| Units on a scale | BMN165 20mg/Day | Placebo 20mg/Day | BMN165 40mg/Day | Placebo 40mg/Day |
|---|---|---|---|---|
| Baseline | 5.9 ± 4.70 | 5.0 ± 4.26 | 6.0 ± 6.45 | 2.9 ± 3.68 |
| Change from Baseline Part 2 Week 8 | 1.1 ± 3.96 | 1.2 ± 3.00 | 0.5 ± 5.36 | -0.4 ± 3.44 |
The long term effect of multiple dose levels of BMN165 on blood phe concentration in subjects who are administered BMN165 using pre-filled syringes.
| µmol/L | BMN165 < 20 mg/Day - Part 4 | BMN165 20 to < 40 mg/Day - Part 4 | BMN165 40 to < 60 mg/Day - Part 4 | BMN165 >= 60 mg/Day - Part 4 | BMN165 All Dose - Part 4 |
|---|---|---|---|---|---|
| Change from Baseline to Part 4 Week 57 | -1004.9 ± 541.19 | -984.0 ± 531.33 | -810.2 ± 595.24 | -662.3 ± 465.61 | -839.5 ± 562.74 |
| Change from Baseline to Part 4 Week 105 | -1015.3 ± 557.00 | -1109.2 ± 474.25 | -858.5 ± 593.73 | -641.0 ± 568.67 | -890.8 ± 578.38 |
| Change from Baseline to Part 4 Week 161 | -1006.5 ± 514.76 | -1111.9 ± 519.40 | -662.8 ± 433.80 | -808.6 ± 558.22 | -882.0 ± 528.61 |
| Change from Baseline to Part 4 Week 209 | -897.3 ± 494.41 | -1020.4 ± 495.79 | -541.6 ± 245.83 | -961.7 ± 339.92 | -842.3 ± 418.37 |
| Change from Baseline to Part 4 Week 249 | -1059.5 ± 160.51 | — | — | -1314.0 ± NA | -1144.3 ± 185.67 |
Phenylketonuria (PKU) Total Mood Disturbance (TMD) Profile of Mood States (POMS) PKU POMS TMD is self-rated, each item in the tool is rated using a five-point Likert scale: 0 (not at all), 1 (a little), 2 (moderately), 3 (quite a bit), and 4 (extremely).
| Units on a scale | BMN165 20mg/Day | Placebo 20mg/Day | BMN165 40mg/Day | Placebo 40mg/Day |
|---|---|---|---|---|
| Baseline | 7.1 ± 14.18 | 8.6 ± 10.84 | 8.9 ± 12.28 | 5.0 ± 8.56 |
| Change from Baseline Part 2 Week 8 | 4.8 ± 12.63 | 4.3 ± 11.96 | -2.0 ± 10.25 | 0.0 ± 14.08 |
PKU POMS confusion mood domain (referred to as the confusion subscale) is self-rated, each item in the tool is rated using a five-point Likert scale: 0 (not at all), 1 (a little), 2 (moderately), 3 (quite a bit), and 4 (extremely).
| Units on a scale | BMN165 20mg/Day | Placebo 20mg/Day | BMN165 40mg/Day | Placebo 40mg/Day |
|---|---|---|---|---|
| Baseline | 2.0 ± 2.09 | 2.1 ± 1.49 | 2.4 ± 2.02 | 1.2 ± 1.53 |
| Change from Baseline Part 2 Week 8 | 0.8 ± 2.79 | 1.4 ± 2.47 | -0.3 ± 1.84 | 0.5 ± 2.22 |
Full-length POMS TMD is self-rated, each item in the tool is rated using a five-point Likert scale: 0 (not at all), 1 (a little), 2 (moderately), 3 (quite a bit), and 4 (extremely).
| Units on a scale | BMN165 20mg/Day | Placebo 20mg/Day | BMN165 40mg/Day | Placebo 40mg/Day |
|---|---|---|---|---|
| Baseline | 16.2 ± 35.63 | 18.1 ± 28.26 | 24.3 ± 35.38 | 13.3 ± 21.63 |
| Change from Baseline Part 2 Week 8 | 13.1 ± 30.73 | 7.3 ± 26.23 | -3.2 ± 26.63 | -1.7 ± 29.34 |
Collected over Up to 301 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1 - 20 mg/Day | 0/86 (0%) | 6/86 (7%) | 70/86 (81.4%) |
| Part 1 - 40 mg/Day | 0/78 (0%) | 2/78 (2.6%) | 59/78 (75.6%) |
| Part 2 - 20 mg/Day Active | 0/34 (0%) | 0/34 (0%) | 27/34 (79.4%) |
| Part 2 - 40 mg/Day Active | 0/32 (0%) | 2/32 (6.3%) | 28/32 (87.5%) |
| Part 2 - 20 mg/Day Placebo | 0/15 (0%) | 1/15 (6.7%) | 14/15 (93.3%) |
| Part 2 - 40 mg/Day Placebo | 0/14 (0%) | 0/14 (0%) | 13/14 (92.9%) |
| Part 3 - Stay on Active 20 mg/Day | 0/23 (0%) | 1/23 (4.3%) | 19/23 (82.6%) |
| Part 3 - Stay on Active 40 mg/Day | 0/18 (0%) | 0/18 (0%) | 15/18 (83.3%) |
| Part 3 - Switch From Placebo to Active 20 mg/Day | 0/11 (0%) | 0/11 (0%) | 8/11 (72.7%) |
| Part 3 - Switch From Placebo to Active 40 mg/Day | 0/8 (0%) | 0/8 (0%) | 7/8 (87.5%) |
| Part 4 - < 20 mg/Day | 0/67 (0%) | 7/67 (10.4%) | 62/67 (92.5%) |
| Part 4 - 20 to < 40 mg/Day | 0/152 (0%) | 6/152 (3.9%) | 105/152 (69.1%) |
| Part 4 - 40 to < 60 mg/Day | 0/186 (0%) | 16/186 (8.6%) | 178/186 (95.7%) |
| Part 4 - >= 60 mg/Day | 0/89 (0%) | 5/89 (5.6%) | 59/89 (66.3%) |
| Event | Part 1 - 20 mg/Day | Part 1 - 40 mg/Day | Part 2 - 20 mg/Day Active | Part 2 - 40 mg/Day Active | Part 2 - 20 mg/Day Placebo | Part 2 - 40 mg/Day Placebo | Part 3 - Stay on Active 20 mg/Day | Part 3 - Stay on Active 40 mg/Day | Part 3 - Switch From Placebo to Active 20 mg/Day | Part 3 - Switch From Placebo to Active 40 mg/Day | Part 4 - < 20 mg/Day | Part 4 - 20 to < 40 mg/Day | Part 4 - 40 to < 60 mg/Day | Part 4 - >= 60 mg/Day |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Blood creatine phosphokinase increasedInvestigations | 0/86 | 0/78 | 0/34 | 0/32 | 1/15 | 0/14 | 1/23 | 0/18 | 0/11 | 0/8 | 1/67 | 0/152 | 0/186 | 0/89 |
| AgitationPsychiatric disorders | 0/86 | 0/78 | 0/34 | 1/32 | 0/15 | 0/14 | 0/23 | 0/18 | 0/11 | 0/8 | 0/67 | 0/152 | 0/186 | 0/89 |
| DepressionPsychiatric disorders | 0/86 | 0/78 | 0/34 | 1/32 | 0/15 | 0/14 | 0/23 | 0/18 | 0/11 | 0/8 | 0/67 | 1/152 | 0/186 | 0/89 |
| Road Traffic AccidentInjury, poisoning and procedural complications | 0/86 | 1/78 | 0/34 | 0/32 | 0/15 | 0/14 | 0/23 | 0/18 | 0/11 | 0/8 | 2/67 | 0/152 | 0/186 | 0/89 |
| Anaphylactic ReactionImmune system disorders | 0/86 | 0/78 | 0/34 | 0/32 | 0/15 | 0/14 | 0/23 | 0/18 | 0/11 | 0/8 | 0/67 | 1/152 | 4/186 | 0/89 |
| Blood pressure increasedInvestigations | 0/86 | 0/78 | 0/34 | 0/32 | 0/15 | 0/14 | 0/23 | 0/18 | 0/11 | 0/8 | 1/67 | 0/152 | 0/186 | 0/89 |
| Abortion missedPregnancy, puerperium and perinatal conditions | 0/86 | 0/78 | 0/34 | 0/32 | 0/15 | 0/14 | 0/23 | 0/18 | 0/11 | 0/8 | 1/67 | 0/152 | 0/186 | 0/89 |
| Gestational hypertensionPregnancy, puerperium and perinatal conditions | 0/86 | 0/78 | 0/34 | 0/32 | 0/15 | 0/14 | 0/23 | 0/18 | 0/11 | 0/8 | 1/67 | 0/152 | 0/186 | 0/89 |
| EndometriosisReproductive system and breast disorders | 0/86 | 0/78 | 0/34 | 0/32 | 0/15 | 0/14 | 0/23 | 0/18 | 0/11 | 0/8 | 1/67 | 0/152 | 0/186 | 0/89 |
| HypersensitivityImmune system disorders | 0/86 | 1/78 | 0/34 | 0/32 | 0/15 | 0/14 | 0/23 | 0/18 | 0/11 | 0/8 | 0/67 | 1/152 | 2/186 | 0/89 |
| Event | Part 1 - 20 mg/Day | Part 1 - 40 mg/Day | Part 2 - 20 mg/Day Active | Part 2 - 40 mg/Day Active | Part 2 - 20 mg/Day Placebo | Part 2 - 40 mg/Day Placebo | Part 3 - Stay on Active 20 mg/Day | Part 3 - Stay on Active 40 mg/Day | Part 3 - Switch From Placebo to Active 20 mg/Day | Part 3 - Switch From Placebo to Active 40 mg/Day | Part 4 - < 20 mg/Day | Part 4 - 20 to < 40 mg/Day | Part 4 - 40 to < 60 mg/Day | Part 4 - >= 60 mg/Day |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 9/86 | 13/78 | 7/34 | 2/32 | 1/15 | 2/14 | 3/23 | 0/18 | 3/11 | 2/8 | 16/67 | 33/152 | 64/186 | 22/89 |
| NasopharyngitisInfections and infestations | 7/86 | 11/78 | 4/34 | 1/32 | 0/15 | 1/14 | 2/23 | 0/18 | 0/11 | 0/8 | 15/67 | 27/152 | 59/186 | 19/89 |
| HeadacheNervous system disorders | 16/86 | 12/78 | 6/34 | 2/32 | 3/15 | 4/14 | 2/23 | 3/18 | 1/11 | 0/8 | 20/67 | 29/152 | 59/186 | 24/89 |
| Upper respiratory tract infectionInfections and infestations | 8/86 | 5/78 | 1/34 | 0/32 | 3/15 | 2/14 | 3/23 | 2/18 | 1/11 | 0/8 | 14/67 | 29/152 | 51/186 | 10/89 |
| Injection site reactionGeneral disorders | 13/86 | 7/78 | 4/34 | 1/32 | 1/15 | 1/14 | 3/23 | 1/18 | 1/11 | 0/8 | 6/67 | 14/152 | 46/186 | 11/89 |
| FatigueGeneral disorders | 8/86 | 3/78 | 4/34 | 3/32 | 3/15 | 0/14 | 5/23 | 4/18 | 0/11 | 1/8 | 10/67 | 8/152 | 14/186 | 10/89 |
| Injection site bruisingGeneral disorders | 9/86 | 7/78 | 2/34 | 1/32 | 2/15 | 1/14 | 2/23 | 1/18 | 0/11 | 0/8 | 5/67 | 14/152 | 41/186 | 12/89 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 4/86 | 2/78 | 1/34 | 0/32 | 3/15 | 0/14 | 0/23 | 0/18 | 1/11 | 0/8 | 9/67 | 12/152 | 20/186 | 8/89 |
| Amino acid level decreasedInvestigations | 3/86 | 1/78 | 0/34 | 0/32 | 0/15 | 0/14 | 0/23 | 1/18 | 0/11 | 0/8 | 9/67 | 13/152 | 37/186 | 13/89 |
| RashSkin and subcutaneous tissue disorders | 2/86 | 6/78 | 2/34 | 3/32 | 1/15 | 0/14 | 2/23 | 2/18 | 0/11 | 1/8 | 7/67 | 8/152 | 34/186 | 14/89 |
All Subjects consists of subjects participated in 165-302 Part 1, 2, 3 and 4.
| Age, Continuous(yrs) | All Subjects |
|---|---|
| Mean | 29.22 ± 8.74 |
| Age, Customized(Participants) | All Subjects |
|---|---|
| 16 - <18 years | 11 |
| 18 - <66 years | 204 |
| Sex: Female, Male(Participants) | All Subjects |
|---|---|
| Female | 105 |
| Male | 110 |
| Race/Ethnicity, Customized(Participants) | All Subjects |
|---|---|
| American Indian or Alaska Native | 1 |
| White | 211 |
| Black/African American | 2 |
Plan to share: No
Ran from Jul 2013 to primary completion in Jan 2016, 29 months.
Results were first posted in Jul 2019, 3 years 5 months after primary completion. A results delay was requested in Dec 2017.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pegvaliase